Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference

Core Insights - Genelux Corporation is a late clinical-stage immuno-oncology company focused on developing next-generation oncolytic immunotherapies for aggressive and difficult-to-treat solid tumors [3] Company Participation - Thomas Zindrick, President, CEO, and Chairman of the Board, along with Matt Pulisic, Chief Financial Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 12:00 p.m. ET in New York, NY [1] Clinical Trials - Olvi-Vec, the company's lead product, is currently being evaluated in two U.S.-based clinical trials: - OnPrime/GOG-3076, a Phase 3 trial for platinum-resistant/refractory ovarian cancer [3] - VIRO-25, a Phase 2 trial for non-small-cell lung cancer [3] - Additionally, Olvi-Vec is being evaluated in a China-based Phase 1b trial for recurrent small-cell lung cancer [3] Proprietary Technology - The core of Genelux's discovery and development efforts is its proprietary CHOICE™ platform, which has led to the development of an extensive library of oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec [3]